Pitfalls in accurate estimation of overdiagnosis: Implications for screening policy and compliance

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Feig, Stephen A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER SCREENING; DIAGNOSTIC ERROR; EDITORIAL; FOLLOW UP; HEALTH CARE POLICY; HUMAN; INTRADUCTAL CARCINOMA; MEASUREMENT ACCURACY; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE;

BREAST NEOPLASMS; DIAGNOSTIC ERRORS; EARLY DETECTION OF CANCER; FEMALE; HUMANS;

EID: 84883274773     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3448     Document Type: Editorial

References (14)

1. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res 2013, 15:R41. 10.1186/bcr3427, 3706885, 23680223.
2. Kalager M, Adami H, Bretthauer M, Tamimi R. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012, 156:491-499. 10.7326/0003-4819-156-7-201204030-00005, 22473436.
3. Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786. Independent UK Panel on Breast Cancer Screening.
4. Puliti D, Duffy SW, de Koning H, Lynge E, Zappa M, Paci E, EUROSCREEN Working Group Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012, 19(Suppl 1):42-56. EUROSCREEN Working Group.
5. Yen A M-F, Duffy SW, Chen TH, Chen LS, Chiu SY, Fann JC, Wu WY, Su CW, Smith RA, Tabár L. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two County Trial of Mammograpy screening. Cancer 2012, 118:5728-5732. 10.1002/cncr.27580, 22605639.
6. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med 2012, 367:1998-2005. 10.1056/NEJMoa1206809, 23171096.
7. Garfinkel L, Boring CC, Heath CW. Changing trends: an overview of breast cancer incidence and mortality. Cancer 1994, 74(Suppl):222-227.
8. Kopans DB. The New England Journal of Medicine article suggesting overdiagnosis from mammography screening is scientifically incorrect and should be withdrawn. J Am Coll Radiol 2013, 10:317-319. 10.1016/j.jacr.2013.01.024, 23542028.
9. Orenstein P. The problem with pink: our feel-good war on breast cancer. New York Times Magazine 2013, 36-43. 25 April 66-69.
10. McCann J, Treasure P, Duffy S. Modelling the impact of detecting and treating carcinoma in situ in a breast cancer screening programme. J Med Screen 2004, 11:117-125. 10.1258/0969141041732201, 15333269.
11. Yen MF, Tabar L, Vitak B, Smith RA, Chen H-H, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003, 39:1746-1754. 10.1016/S0959-8049(03)00260-0, 12888370.
12. Feig SA. Ductal carcinoma in situ: implications for screening mammography. Radiol Clin North Am 2000, 38:653-669. 10.1016/S0033-8389(05)70192-5, 10943269.
13. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995, 345:1154-1157. 10.1016/S0140-6736(95)90982-6, 7723550.
14. Masood S. Focusing on cancer overdiagnosis and overtreatment: the promise of molecular medicine. Breast J 2013, 19:127-129. 10.1111/tbj.12095, 23458217.